Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial

BACKGROUND AND PURPOSE: Pulmonary arterial hypertension (PAH) is an incurable, incapacitating disorder resulting from increased pulmonary vascular resistance, pulmonary arterial remodelling, and right ventricular failure. In preclinical models, the combination of a PDE5 inhibitor (PDE5i) with a nepr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Pharmacol
Autores principales: Hobbs, Adrian J., Moyes, Amie J., Baliga, Reshma S., Ghedia, Dipa, Ochiel, Rachel, Sylvestre, Yvonne, Doré, Caroline J., Chowdhury, Kashfia, Maclagan, Kate, Quartly, Harriet L., Sofat, Reecha, Smit, Angelique, Schreiber, Benjamin E., Coghlan, Gerry J., MacAllister, Raymond J.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Papers
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651846/
https://ncbi.nlm.nih.gov/pubmed/30761523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14621
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares